×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARAY – accuray incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARAY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
09:27 am
aray
Accuray Loses US$24m Market Value But Insiders See Windfall Of US$23k [Yahoo! Finance]
Low
Report
Accuray Loses US$24m Market Value But Insiders See Windfall Of US$23k [Yahoo! Finance]
12/18
08:48 am
aray
Reasons to Add McKesson Stock to Your Portfolio Right Now [Yahoo! Finance]
Medium
Report
Reasons to Add McKesson Stock to Your Portfolio Right Now [Yahoo! Finance]
12/18
08:14 am
aray
Ablation Technology Market Insights, Key Drivers and Opportunities | Exactitude Consultancy [Yahoo! Finance]
High
Report
Ablation Technology Market Insights, Key Drivers and Opportunities | Exactitude Consultancy [Yahoo! Finance]
12/18
07:36 am
aray
New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat [Yahoo! Finance]
Medium
Report
New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat [Yahoo! Finance]
12/18
07:35 am
aray
New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat
Medium
Report
New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat
12/16
10:11 am
aray
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Accuray (ARAY) [Yahoo! Finance]
Neutral
Report
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Accuray (ARAY) [Yahoo! Finance]
12/11
10:46 am
aray
Radiotherapy Market to Hit USD 9.62 Billion by 2030 with 4.9% CAGR | MarketsandMarkets™ [Yahoo! Finance]
Low
Report
Radiotherapy Market to Hit USD 9.62 Billion by 2030 with 4.9% CAGR | MarketsandMarkets™ [Yahoo! Finance]
12/10
01:09 pm
aray
Here's Why You Should Add Accuray Stock in Your Portfolio Now [Yahoo! Finance]
Low
Report
Here's Why You Should Add Accuray Stock in Your Portfolio Now [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/11
04:02 pm
aray
Form 8-K ACCURAY INC For: Dec 06
Medium
Report
Form 8-K ACCURAY INC For: Dec 06
12/9
04:10 pm
aray
Form 3 ACCURAY INC For: Dec 02 Filed by: MURPHY MICHAEL JOHN
Low
Report
Form 3 ACCURAY INC For: Dec 02 Filed by: MURPHY MICHAEL JOHN
12/3
04:20 pm
aray
Form 4 ACCURAY INC For: Nov 29 Filed by: Chew Jesse
Medium
Report
Form 4 ACCURAY INC For: Nov 29 Filed by: Chew Jesse
12/3
04:20 pm
aray
Form 4 ACCURAY INC For: Nov 29 Filed by: Chalke Sandeep
Medium
Report
Form 4 ACCURAY INC For: Nov 29 Filed by: Chalke Sandeep
12/3
04:20 pm
aray
Form 4 ACCURAY INC For: Nov 29 Filed by: WHITTERS JOSEPH E
Medium
Report
Form 4 ACCURAY INC For: Nov 29 Filed by: WHITTERS JOSEPH E
12/3
04:20 pm
aray
Form 4 ACCURAY INC For: Nov 29 Filed by: HUSS BEVERLY A
Medium
Report
Form 4 ACCURAY INC For: Nov 29 Filed by: HUSS BEVERLY A
12/3
04:20 pm
aray
Form 4 ACCURAY INC For: Nov 29 Filed by: Pervaiz Ali
Medium
Report
Form 4 ACCURAY INC For: Nov 29 Filed by: Pervaiz Ali
12/3
04:20 pm
aray
Form 4 ACCURAY INC For: Nov 30 Filed by: Hoge Michael
Medium
Report
Form 4 ACCURAY INC For: Nov 30 Filed by: Hoge Michael
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/28
Q3/2020 3/31/2020 EPS 0.030 ZacksConsensus -0.030 ActVsEst 0.060 - Beat
15.4%
1/28 Q2/2020 12/31/2019 EPS 0.120 ZacksConsensus -0.070 ActVsEst 0.190 - Beat 13.4%
12/25 Accuray Incorporated (NASDAQ: ARAY) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 8.2%
11/4 Form 4 ACCURAY INC For: Oct 31 Filed by: Chew Jesse 7.6%
11/1 Form 4 ACCURAY INC For: Oct 31 Filed by: Winter Suzanne C 7.4%
9/6 Form 4 ACCURAY INC For: Sep 04 Filed by: WHITTERS JOSEPH E 6.0%
2/11 Accuray Incorporated (NASDAQ: ARAY) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.6%
1/16 Accuray To Report Fiscal 2020 Second Quarter Financial Results on January 28, 2020 5.2%
1/21 Accuray Incorporated (NASDAQ: ARAY) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $9.50 price target on the stock. 5.2%
7/19 Accuray To Report Fiscal 2019 Fourth Quarter and Full Year Financial Results on August 15, 2019 4.7%
1/28 Q2/2020 12/31/2019 EPS 0.120 ZacksConsensus -0.070 ActVsEst 0.190 - Beat 13.4%
12/25 Accuray Incorporated (NASDAQ: ARAY) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 8.2%
11/4 Form 4 ACCURAY INC For: Oct 31 Filed by: Chew Jesse 7.6%
11/1 Form 4 ACCURAY INC For: Oct 31 Filed by: Winter Suzanne C 7.4%
9/6 Form 4 ACCURAY INC For: Sep 04 Filed by: WHITTERS JOSEPH E 6.0%
2/11 Accuray Incorporated (NASDAQ: ARAY) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 5.6%
1/16 Accuray To Report Fiscal 2020 Second Quarter Financial Results on January 28, 2020 5.2%
1/21 Accuray Incorporated (NASDAQ: ARAY) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $9.50 price target on the stock. 5.2%
7/19 Accuray To Report Fiscal 2019 Fourth Quarter and Full Year Financial Results on August 15, 2019 4.7%
TOP News Decliners
1/30
Accuray Incorporated (NASDAQ: ARAY) was upgraded by analysts at TheStreet from a "d" rating to a "c-" rating.
-11.0%
3/10 Accuray Incorporated (NASDAQ: ARAY) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -8.5%
8/15 Q4/2019 6/30/2019 EPS -0.020 ZacksConsensus 0.030 ActVsEst (0.050) - Miss -7.5%
8/2 Form 8-K ACCURAY INC For: Jul 30 -6.7%
4/28 Accuray Inc (ARAY) Q3 2020 Earnings Call Transcript [The Motley Fool] -5.9%
10/30 Accuray Drifting, And Critical Mass Seems Far Away [Seeking Alpha] -5.5%
9/17 Data Published in The Lancet Oncology Suggest CyberKnife® Prostate Patients Experienced Lower Levels of Acute Genitourinary Toxicity (Grade 2 or Higher) Than Patients Treated on a Conventional Linear Accelerator -5.2%
10/29 Q1/2020 9/30/2019 EPS -0.110 ZacksConsensus -0.100 ActVsEst (0.010) - Miss -4.8%
8/22 Form 8-K ACCURAY INC For: Aug 16 -4.7%
2/5 Studies Support Use of the Accuray TomoTherapy® System for Advanced Rectal Cancer to Improve Treatment Efficacy and Reduce Side Effects -4.3%
3/10 Accuray Incorporated (NASDAQ: ARAY) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -8.5%
8/15 Q4/2019 6/30/2019 EPS -0.020 ZacksConsensus 0.030 ActVsEst (0.050) - Miss -7.5%
8/2 Form 8-K ACCURAY INC For: Jul 30 -6.7%
4/28 Accuray Inc (ARAY) Q3 2020 Earnings Call Transcript [The Motley Fool] -5.9%
10/30 Accuray Drifting, And Critical Mass Seems Far Away [Seeking Alpha] -5.5%
9/17 Data Published in The Lancet Oncology Suggest CyberKnife® Prostate Patients Experienced Lower Levels of Acute Genitourinary Toxicity (Grade 2 or Higher) Than Patients Treated on a Conventional Linear Accelerator -5.2%
10/29 Q1/2020 9/30/2019 EPS -0.110 ZacksConsensus -0.100 ActVsEst (0.010) - Miss -4.8%
8/22 Form 8-K ACCURAY INC For: Aug 16 -4.7%
2/5 Studies Support Use of the Accuray TomoTherapy® System for Advanced Rectal Cancer to Improve Treatment Efficacy and Reduce Side Effects -4.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: